MAPT and supranuclear palsy, progressive, 1: Tilavonemab, (ABBV-8E12), a recombinant monoclonal antibody that recognizes the N-terminal of misfolded extracellular aggregated tau, a form of tau that has been implicated in the seeding and transneuronal propagation of pathological tau, was being developed by AbbVie and C2N Therapeutics in AD and PSP [92].